F-1/A: NewGenIvf Group Files for Resale of Up to 22 Million Class A Ordinary Shares

NewGenIvf Group Limited is registering the offer and resale of up to 22,027,500 Class A Ordinary Shares by selling securityholders, aiming to satisfy certain registration rights.

Summary

• NewGenIvf Group Limited has filed a registration statement for the resale of up to 22,027,500 Class A Ordinary Shares by its selling securityholders.
• These shares consist of shares issued to Genetics & IVF Institute, Inc. (GIVF), A SPAC Holdings Group Corp. (ASPAC), shares issuable to JAK Opportunities VI LLC upon conversion of notes and warrants, and shares issuable to White Lion Capital, LLC under a Common Stock Purchase Agreement.
• The company will not receive any proceeds from the sale of these shares by the selling securityholders.
• However, NewGenIvf may receive up to $500 million from the sale of Class A Ordinary Shares to White Lion under the White Lion Purchase Agreement, and proceeds from the conversion of notes and warrants, which will be used for working capital and general corporate purposes.
• The company's Class A Ordinary Shares currently trade on The Nasdaq Capital Market under the symbol NIVF, with the last reported closing price on May 16, 2025, being $2.95.
• NewGenIvf qualifies as a foreign private issuer and a controlled company, making it eligible for reduced public company reporting requirements.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on disclosing the details of the share resale and potential capital raising. The potential dilution risk is a negative factor, while the potential capital injection is a positive.

Positives

• The registration allows selling securityholders to resell their shares, potentially increasing liquidity.
• The company may receive up to $500 million from the sale of shares to White Lion, providing additional capital.
• The company qualifies as a foreign private issuer and a controlled company, reducing reporting requirements.

Negatives

• The resale of a large number of shares could depress the market price of the company's Class A Ordinary Shares.
• The company will not receive any proceeds from the sale of shares by the selling securityholders.
• The company's ability to raise capital through the sale of additional equity securities could be impaired.

Risks

• The sale of a large number of shares could depress the market price of the company's Class A Ordinary Shares.
• The company's ability to raise capital through the sale of additional equity securities could be impaired.
• The actual proceeds from White Lion may be less than $500 million, depending on the number of shares sold and the price at which they are sold.

Future Outlook

The company may receive up to $500 million in gross proceeds under the White Lion Purchase Agreement from sales of Class A Ordinary Shares that we may elect to make to White Lion pursuant to the White Lion Purchase Agreement. In addition, we may receive proceeds from conversion of the Additional Notes, the Exchange Notes, the Warrants and the New CB Initial Note. All proceeds from the conversion of the Additional Notes, Exchange Notes, Warrants, New CB Initial Note and the sales of Class A Ordinary Shares to White Lion will be used for working capital and other general corporate purposes.

Industry Context

This announcement is typical for companies that have recently completed a business combination and need to register shares for resale by existing shareholders. The potential dilution effect is a common risk factor in such offerings.

Stakeholder Impact

• Shareholders may experience a decrease in the market price of the company's Class A Ordinary Shares due to the potential resale of a large number of shares.
• The company's ability to raise capital through the sale of additional equity securities could be impaired.
• The company may use the proceeds from the sale of shares to White Lion and the conversion of notes and warrants for working capital and general corporate purposes, potentially benefiting the company's operations and growth.

Next Steps

• The selling securityholders may offer all or part of the securities for resale from time to time through public or private transactions.
• The company may elect to sell its Class A Ordinary Shares to White Lion pursuant to the White Lion Purchase Agreement.

Key Dates

Keywords

Class A Ordinary Shares, resale, NewGenIvf, White Lion, JAK Opportunities, registration statement, securities, offering, NIVF